Tiziana Life Sciences (TLSA)

Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

Company profile

Ticker

TLSA

Exchange

NASDAQ

Website

www.tizianalifesciences.com

CEO

Mr. Gabriele Marco Antonio Cerrone M.B.A.

Incorporated

Wisconsin

Location

Wisconsin

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SIC)

State Commercial Banks

Ally Financial • International Business Machines • Phillips 66 • Hilton Worldwide • Associated Banc-Corp • Commerce Bancshares • Arch Capital • First Citizens BancShares • Prosperity Bancshares • Hancock Whitney ...

Former names

Tiziana Life Sciences plc

SEC CIK

0001723069

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

TLSA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

6-K

Tiziana Life Sciences Announces $4 Million Grant Awarded by National Institutes of Health to Study Anti-CD3 in Alzheimer’s Disease

19 Sep 24

6-K

Tiziana Life Sciences Appoints New Chief Executive Officer

19 Aug 24

6-K

Report of Foreign Private Issuer

14 Aug 24

6-K

Report of Foreign Private Issuer

1 Aug 24

6-K

Tiziana Life Sciences Granted FDA Fast Track Designation

24 Jul 24

6-K

Tiziana Receives $3.4 Million in Non-Dilutive Funding

28 Jun 24

6-K

Report of Foreign Private Issuer

26 Jun 24

6-K

FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis

11 Jun 24

6-K

Report of Foreign Private Issuer

6 Jun 24

6-K

Report of Foreign Private Issuer

4 Jun 24

Latest ownership filings

SC 13G

Fonda Laura Natalia Monica

Altium Capital Management LP

16 Feb 21

SC 13G/A

Empery Asset Management, LP

26 Jan 21

SC 13G

Altium Capital Management LP

12 Aug 20

SC 13G

Empery Asset Management, LP

17 Mar 20

Financial summary

Financial statements Chart TLSA financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q4 2021

TLSA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	24	EXIT
Opened positions	0	6	EXIT
Closed positions	24	5	+380.0%
Increased positions	0	7	EXIT
Reduced positions	0	5	EXIT

13F shares	Current	Prev Q	Change
Total value	0.00	2.04 mm	EXIT
Total shares	0.00	1.40 mm	EXIT
Total puts	0.00	0.00
Total calls	0.00	33.00 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Bought/sold	Change
BLK BlackRock	-550.73 k	EXIT
STT State Street	-283.67 k	EXIT
MS Morgan Stanley	-179.46 k	EXIT
Geode Capital Management	-133.87 k	EXIT
BAC Bank of America	-50.31 k	EXIT
Ausdal Financial Partners	-46.90 k	EXIT
Marshall Wace	-41.46 k	EXIT
Capital Asset Advisory Services	-37.83 k	EXIT
Susquehanna International	-23.19 k	EXIT
Two Sigma Securities	-18.58 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.